Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVKDNASDAQ:IMNPNASDAQ:KZRNASDAQ:LVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$14.14-4.4%$16.73$5.70▼$22.90$27.43M1.4639,723 shs24,082 shsIMNPImmune Pharmaceuticals$0.00$0.00▼$0.48$8.14MN/A12.29 million shsN/AKZRKezar Life Sciences$4.13-1.7%$4.70$3.62▼$9.18$30.17M0.6158,519 shs81,286 shsLVTXLAVA Therapeutics$1.27+1.6%$1.26$0.85▼$2.99$33.41M0.46159,266 shs51,797 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics-4.39%-13.09%-8.48%-26.32%+1,413,999,900.00%IMNPImmune Pharmaceuticals0.00%0.00%0.00%0.00%0.00%KZRKezar Life Sciences-1.67%+1.08%-4.40%-29.64%-47.69%LVTXLAVA Therapeutics+1.60%+1.36%+9.48%+34.96%-56.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVKDCadrenal Therapeutics2.822 of 5 stars3.55.00.00.01.51.70.6IMNPImmune PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKZRKezar Life Sciences4.1356 of 5 stars3.23.00.04.63.11.70.6LVTXLAVA Therapeutics2.3191 of 5 stars3.05.00.00.02.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVKDCadrenal Therapeutics 3.00Buy$32.00126.31% UpsideIMNPImmune Pharmaceuticals 0.00N/AN/AN/AKZRKezar Life Sciences 2.33Hold$39.50856.42% UpsideLVTXLAVA Therapeutics 2.00Hold$3.17149.34% UpsideCurrent Analyst Ratings BreakdownLatest IMNP, LVTX, CVKD, and KZR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.502/28/2025KZRKezar Life SciencesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Outperform2/27/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$2.00 ➝ $1.50(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVKDCadrenal TherapeuticsN/AN/AN/AN/A$8.86 per shareN/AIMNPImmune PharmaceuticalsN/AN/AN/AN/AN/AN/AKZRKezar Life Sciences$7M4.31N/AN/A$25.80 per share0.16LVTXLAVA Therapeutics$11.98M2.79N/AN/A$1.95 per share0.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVKDCadrenal Therapeutics-$8.36M-$9.26N/AN/AN/AN/A-142.95%-118.40%N/AIMNPImmune PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AKZRKezar Life Sciences-$101.87M-$11.55N/AN/AN/AN/A-54.95%-46.11%5/15/2025 (Estimated)LVTXLAVA Therapeutics-$41.97M-$0.93N/AN/AN/AN/A-62.22%-29.37%5/20/2025 (Estimated)Latest IMNP, LVTX, CVKD, and KZR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025LVTXLAVA Therapeutics-$0.37-$0.13+$0.24-$0.13N/AN/A5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A5/8/2025Q1 2025CVKDCadrenal Therapeutics-$1.64-$2.09-$0.45-$2.09N/AN/A3/28/2025Q4 2024LVTXLAVA Therapeutics-$0.32-$0.14+$0.18-$0.14$2.40 million$2.50 million3/25/2025Q4 2024 & Study ResultKZRKezar Life Sciences-$2.71-$2.77-$0.06-$2.77N/AN/A3/13/2025Q4 2024CVKDCadrenal Therapeutics-$1.71-$2.74-$1.03-$2.74N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AIMNPImmune PharmaceuticalsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVKDCadrenal TherapeuticsN/A3.693.69IMNPImmune PharmaceuticalsN/AN/AN/AKZRKezar Life Sciences0.057.657.65LVTXLAVA TherapeuticsN/A5.365.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVKDCadrenal Therapeutics7.92%IMNPImmune Pharmaceuticals1.43%KZRKezar Life Sciences67.90%LVTXLAVA TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCVKDCadrenal Therapeutics48.62%IMNPImmune Pharmaceuticals3.85%KZRKezar Life Sciences9.30%LVTXLAVA Therapeutics0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVKDCadrenal Therapeutics41.94 million916,000Not OptionableIMNPImmune PharmaceuticalsN/A49.31 millionN/ANot OptionableKZRKezar Life Sciences607.31 million6.62 millionNot OptionableLVTXLAVA Therapeutics6026.31 million26.08 millionOptionableIMNP, LVTX, CVKD, and KZR HeadlinesRecent News About These CompaniesLAVA Reports First Quarter 2025 Financial Results, Provides Business UpdateMay 14 at 7:30 AM | globenewswire.comLAVA Therapeutics (LVTX) Projected to Post Quarterly Earnings on TuesdayMay 13 at 2:41 AM | americanbankingnews.comLAVA Therapeutics Granted Full Waiver for RVO Payment Obligation | LVTX Stock NewsApril 16, 2025 | gurufocus.comLAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise AgencyApril 16, 2025 | quiverquant.comLAVA Therapeutics (LVTX) Secures $5.1 Million Debt Waiver from Netherlands Enterprise Agency | ...April 16, 2025 | gurufocus.comLAVA Therapeutics Granted Full Waiver for RVO Payment ObligationApril 16, 2025 | globenewswire.comLava Therapeutics reports Q4 EPS (14c) vs. (24c) last yearMarch 29, 2025 | markets.businessinsider.comLAVA Therapeutics GAAP EPS of -$0.14, revenue of $4.99MMarch 28, 2025 | seekingalpha.comLAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateMarch 28, 2025 | globenewswire.comAnalyst Downgrades LAVA Therapeutics, Sees Pipeline OverhangFebruary 28, 2025 | benzinga.comCautious Stance on LAVA Therapeutics Amid Strategic Review and Workforce ReductionFebruary 27, 2025 | tipranks.comLava Therapeutics announces evaluation of strategic optionsFebruary 26, 2025 | markets.businessinsider.comLAVA Therapeutics (NASDAQ:LVTX) Stock Quotes, Forecast and News SummaryFebruary 26, 2025 | benzinga.comLava Therapeutics trims workforce by 30% to preserve cashFebruary 25, 2025 | bizjournals.comSerina Therapeutics Appoints Karen J. Wilson to Board of DirectorsJanuary 14, 2025 | quiverquant.comLAVA Therapeutics Doses First Patient in Phase 1 Study of Bispecific Gammabody® LAVA-1266 for CD123-Expressing Blood CancersJanuary 10, 2025 | quiverquant.comLAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological CancersJanuary 10, 2025 | globenewswire.comLAVA Therapeutics to Transition to U.S. Domestic IssuerJanuary 2, 2025 | tipranks.comLeerink Partners Downgrades LAVA Therapeutics N.V. (LVTX)December 13, 2024 | msn.comJMP Securities downgrades LAVA Therapeutics (LVTX) to a HoldDecember 11, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMNP, LVTX, CVKD, and KZR Company DescriptionsCadrenal Therapeutics NASDAQ:CVKD$14.14 -0.65 (-4.39%) As of 05/14/2025 04:00 PM EasternCadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Immune Pharmaceuticals NASDAQ:IMNPImmune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.Kezar Life Sciences NASDAQ:KZR$4.13 -0.07 (-1.67%) As of 05/14/2025 04:00 PM EasternKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.LAVA Therapeutics NASDAQ:LVTX$1.27 +0.02 (+1.60%) As of 05/14/2025 04:00 PM EasternLAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
